The company is in its growth phase. Post acquisition of the assets of Apex Drugs, we have a large and diversified product portfolio, large distribution network, and penetration into the emerging markets of South and Central America and Africa. We see a clear upward trend for the next five years and believe that investors can share and grow with the company in the years to come.

A lot of patents will expire by 2014 and it is a huge opportunity for generic and API companies, as it opens up new marketing avenues. We see exciting times for pharma industry.

The company has large manufacturing facilities and a wide range of formulations and captive API manufacturing capabilities. Formulations are being registered within India and emerging markets at a fast pace. This will ensure healthy growth for the company in the years to come.

We are among the few mid-sized companies that are totally integrated, from APIs to formulations, and a presence in the entire value chain with our branded formulations and distribution network. This differentiates us from other mid-sized pharma companies that have a presence either in APIs or in formulations.

The company has a strong order book in place. The new facilities are shaping up well and we will start commercial production within the next three months. With added capacities, a diversified product range and large distribution network, we see strong growth in the next financial year.